Notice the difference in the messaging - very confident IMO!
26/09 - Biotron expects to have data from these three such trials available in the very near term which puts the Company in a very strong position. These data, if positive, will be central to successfully negotiating and completing a commercial transaction for the Company’s HIV-1 and COVID-19 clinical programs.
Today (24/10) Positive data from these trials across two disease indications will put the Company in a strong position as it over to partner the programs in 2024.
*Note the omission of “if positive” in the second statement….
BIT Price at posting:
8.8¢ Sentiment: Buy Disclosure: Held
